Nucleic Acid Labelling Market

Global Nucleic Acid Labelling Market Size (2022 to 2027)

The global nucleic acid labelling market size is estimated to be growing at a CAGR of 8.65% from 2022 to 2027. The size of the market is predicted to be USD 2683.4 million by 2027 and USD 1772.3 million in 2022.

Nucleic Acid Labelling has many applications in fields of drug discovery and identification of new diseases. Nucleic acids are large complex molecules which carry genetic information. Two major types of nucleic acids are DNA and RNA. DNA has the forward function of hereditary characteristics to next-generation, while RNA carries protein synthesis. Nucleic acids are labelled with tags that facilitate the detection and purification process. Many methods involve chemicals and enzymes for labelling nucleic acids like a corporation of fluorescent tags, radioactive phosphates, and modifications with biotin, which are primarily for biotechnology applications.

MARKET DRIVERS:

Growing healthcare expenditure, increasing funding for R&D in genomics and disease diagnosis, and rising demand for personalized healthcare are some of the key factors driving the global nucleic acid labelling market.

The rise in the investments in research and development centers to introduce new products is the key driving factor for growth. Increasing focus on the genomics is propelling the demand of the market. Using this genome analysis, scientists can customize drugs to make them more effective, thereby improving treatment outcomes. Besides, this approach can be used to detect and diagnose diseases in a particular way by categorizing them by genetic variation rather than symptoms, thereby attracting large numbers of patients to it, which in turn boosts the nucleic acid labeling market.

Initiatives by public and private organizations are accelerating the growth of the nucleic acid labelling market. Increasing prevalence for the design of synthetic genome through different technologies available in the biotechnology field is solely to fuel the demand of the market. Increasing support from the government by changing schemes in favor of ordinary people to present growth opportunities for the market players. Growing disposable income is also one more factor leveraging the demand of the market. Furthermore, the market is led by shifting people's interest in personalized medicine.

The growing incidence of chronic diseases directing to diabetes and other cardiovascular diseases and patient demand for personalized drugs is one of the primary drivers of the nucleic acid labeling market during the forecast period.

With the remarkable development of sequencing technology, various species' genome, from bacteria to humans, has been completely sequenced. Besides, the sequencing speed has been dramatically accelerated by the recent advent of Next Generation Sequencing (NGS) methods, which previously followed conventional capillary sequencing methods. NGS methods analyze different sizes and types of DNA libraries in a more precise, fast, and inexpensive way and in a generalized way, driving the market. NGS provides powerful tools for not only discovering critical biological information such as whole genome sequences, DNA protein variations, and interactions but is also applicable for diagnostic and clinical uses, thus helping your market to grow.

MARKET RESTRAINTS:

However, the government's stringent rules and regulations in approving newly manufactured reference products are limiting the growth of the market. Lack of skilled persons in monitoring the procedures is also restricting the demand of the market. The cost of installing and maintaining overall equipment is a bit high, and it remained a challenging thing for the market developers.

Lack of qualified professionals is a significant setback to the growth of the nucleic acid labeling market during the forecast period. Additionally, due to the lack of a qualified professional to understand the interpretation of HCV test results, when more specific tests should be performed and which test should be considered for this purpose.

Impact of COVID-19 on the global nucleic acid labelling market

The spread of the COVID-19 pandemic has significantly boosted the nucleic acid testing market as nucleic acid test kits are used for the early detection and screening of novel coronavirus. The most important concern of the governments of all countries infected with COVID-19 is the excruciating need to detect and prevent large numbers of patients from presenting with possible infection with the coronavirus. It has resulted in an increased demand for nucleic acid testing. As in March 2020, a drive-thru test for coronavirus nucleic acid testing was opened in Haiden District, Beijing, China. The test drive process was completed in just 3 minutes, and appointments could be made online.

The facility's goal was to step up testing in Beijing and detect more asymptomatic COVID-19 infections. Since the launch, 450 samples have been collected, and nearly 120 people are tested every day. That same month, China's Luohu District Public Health Department collected 18,112 samples between April 24 and April 27, 2020, for nucleic acid testing from students who were about to graduate this year. Besides, demand for these tests will increase as work resumes in all blockaded countries since these tests detect the virus at an early stage. For example, in April 2020, southern China's Guangdong Province required all school staff to undergo nucleic acid testing before returning to work to reduce infection risk. Hence the continued growth of the market. It has put enormous pressure on the diagnostic virology entities as kit supply shortages increase.

Another factor that propels the market to its peak is detection time. With the advancement of technology, testing times are shortened to increase the number of exams per day. It prompted market players to develop rapid and efficient diagnostic kits. For example: According to the Chinese Academy of Sciences, researchers at the Suzhou Institute of Biomedical Engineering and Technology have developed a new nucleic acid test kit for COVID-19 that can confirm cases in 47 minutes on average. In addition to the rapid turnaround time for results, the test kit is also small in size and easy to carry, making it useful for on-site testing. Meanwhile, Abbott Inc. announced in March 2020 the launch of its Molecular Point of Care test kit capable of detecting a positive case in 7 minutes and a negative case in 15 minutes. The company made the kits available during the first week of April 2003 and increased manufacturing to 55,000 tests per day. Therefore, it provides a concrete path for growth during the forecast period between and after the COVID-19 pandemic.

REPORT COVERAGE

This research report on the Global Nucleic Acid Labelling Market has been segmented and sub-segmented based on the product, labelling technique, application, end-user, and region.

Nucleic Acid Labelling Market – By Product:

• Reagents and Kits
  • Labels
    • Radioactive Labels
    • Non-Radioactive Labels
  • Probes
    • Radioactive Probes
    • Non-Radioactive Probes
• Services

Based on Product type, the Reagents and kits segment leads with the highest shares of the Global Nucleic Acid Labelling Market. The growing scale of diagnostic centers with the latest devices is boosting up the growth of the market. The increasing aging population and rise in the incidences of various health disorders are likely to outshine the market demand.

Nucleic Acid Labelling Market – By Labelling Technique:

• PCR
• Nick Translation
• Random Primer
• In-Vitro Transcription
• Reverse Transcription
• End Labelling

Based on the labelling technique, PCR labelling technique moves forward with the most significant shares of the Global Nucleic Acid Labelling Market. The rise in the number of healthcare centers and promising to elevate patient care by reducing the cost for treatment services is magnifying the growth of the market.

Nucleic Acid Labelling Market – By Application

• DNA Sequencing
• Polymerase Chain Reaction
• Fluorescence in Situ Hybridization (FISH)
• Microarrays
• Blotting
• In-Situ Hybridization
• Other Applications

Based on the application, the DNA sequencing application type has the most significant shares of the market. A rising number of genetic diseases is broadening the demand of the market.

Nucleic Acid Labelling Market – By End-Users:

• Diagnostic Centres
• Research Centres
• Hospitals

Based on end-user, Research Centres occupy a significant share owing to increasing government funding to increase research activity and drug discovery.

Nucleic Acid Labelling Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American region is holding a considerable portion of the Global Nucleic Acid Labelling Market by quickly adopting the latest technologies. The growing genomics research is a significant driver of the North American nucleic acid labelling market. Increasing the adoption of personalized healthcare technology is one of the key drivers of market development during the forecast period. The growth of personalized medicine and the identification of genetically engineered and therapeutic areas by the growth of the North America region.

The morbidity of chronic diseases such as cancer, the aging population, the increasing demand for targeted, personalized medicine, and the growing efforts of the government in the North American region are surging the growth of the market to the extent. In recent years, the government has initiated several efforts to supplement the development of the North America nucleic acid labelling market.

The Asia Pacific and Europe are next to North America in leading dominant shares with the rise in the revenue in almost every country and increasing benefits over early diagnosis processes. The Middle East and Africa are to have substantial growth opportunities in the coming years.

KEY MARKET PLAYERS:

Some of the key market participants playing a promising role in the Global Nucleic Acid Labelling Market profiled in this report are Thermo Fisher Scientific, New England Biolabs, PerkinElmer, F. Hoffmann La-Roche AG, General Electric Company, Merck KGaA, Enzo Biochem, Promega Corporation, Vector Laboratories, and Agilent Technologies.

RECENT MARKET DEVELOPMENTS:

• On March 03, 2020, Agilent Technologies has brought three new microarrays into use for the first time during the pregnancy and after newborn research. These surgical instruments are called probes to provide high-quality services in the centers.
• On October 19, 2019, NEBNextRNase H-based RNA depletion protocol kit has undergone the detailed examination of coding and non-coding RNA’s reagents, which was announced by the NEW England Biolabs to support these platforms.
• On September 04, 2018, Promega USA, a leader in bringing new solutions and technical support, collaborated with the CORE diagnostics to leverage Automated Nucleic acid.
• In April 2020 - ThermoFisher Scientific Inc. launched the AcroMetrix Coronavirus 2019 RNA Test to monitor and validate the COVID-19 molecular diagnostic test.